Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty A meta-analysis

被引:17
作者
Huang, Hai-Feng [1 ,2 ]
Li, Shan-Shan [3 ]
Yang, Xian-Teng [1 ,2 ]
Xie, Quan [4 ]
Tian, Xiao-Bin [2 ]
机构
[1] Guizhou Univ, Coll Med, Guiyang, Guizhou, Peoples R China
[2] Guizhou Prov Peoples Hosp, Dept Orthopaed, Guiyang, Guizhou, Peoples R China
[3] Guizhou Prov Peoples Hosp, Dept Anesthesiol, Guiyang, Guizhou, Peoples R China
[4] Guizhou Univ, Coll Big Data & Informat Engn, Guiyang, Guizhou, Peoples R China
基金
中国国家自然科学基金;
关键词
enoxaparin; meta-analysis; rivaroxaban; FACTOR-XA-INHIBITOR; DEEP-VEIN THROMBOSIS; PATIENTS RECEIVING RIVAROXABAN; TOTAL HIP; COST-EFFECTIVENESS; REPLACEMENT SURGERY; THROMBOPROPHYLAXIS; COMPLICATIONS; PROPHYLAXIS; MANAGEMENT;
D O I
10.1097/MD.0000000000013465
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This article analyzed the clinical efficacy and tolerability of rivaroxaban and enoxaparin in patients undergoing total knee arthroplasty (TKA) surgery. Methods: Five randomized, controlled clinical trials on rivaroxaban versus enoxaparin in patients who underwent TKA were identified and included in this meta-analysis. Results: The meta-analysis indicated that rivaroxaban prophylaxis was associated with lower rates of symptomatic venous thromboembolism (VTE) (relative risk[RR]:0.55; 95% confidence interval [CI]: 0.35-0.86; P=.009), symptomatic deep vein thrombosis (DVT) (RR 0.44, 95% CI 0.25-0.80, P=.007), asymptomatic DVT (RR: 0.57; 95% CI: 0.37-0.89; P=.01), distal DVT (RR: 0.62; 95% CI: 0.45-0.85; P=.003) and proximal DVT (RR: 0.42; 95% CI: 0.24-0.75; P=.004). Compared with the enoxaparin group, the incidence of symptomatic pulmonary embolism (PE) (RR: 0.48; 95% CI: 0.19-1.24; P=.13) in the rivaroxaban group was not significantly different. A nonsignificant trend towards all-cause death (RR: 0.38; 95% CI: 0.03-4.92; P=.46) or major bleeding (RR: 1.59; 95% CI: 0.77-3.27; P=.21) risk between rivaroxaban and enoxaparin prophylaxis was found. Conclusion: Compared with the enoxaparin group, the group using rivaroxaban after TKA had a significantly lower rate of symptomatic VTE, symptomatic DVT, asymptomatic DVT, distal DVT, and proximal DVT. Our study shows that rivaroxaban after TKA is more effective than enoxaparin and did not increase major bleeding or all-cause mortality.
引用
收藏
页数:9
相关论文
共 53 条
[1]   Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism [J].
Barco, S. ;
Corti, M. ;
Trinchero, A. ;
Picchi, C. ;
Ambaglio, C. ;
Konstantinides, S. V. ;
Dentali, F. ;
Barone, M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (07) :1436-1442
[2]   Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty [J].
Borris, Lars C. .
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2010, 130 (05) :583-589
[3]  
Borris LC, 2009, EXPERT OPIN PHARMACO, V10, P1083, DOI [10.1517/14656560902835513, 10.1517/14656560902835513 ]
[4]   New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban [J].
Borris, Lars Carl .
VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (04) :855-862
[5]  
Brown Timothy S, 2013, Am J Orthop (Belle Mead NJ), V42, P424
[6]   Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation [J].
Burghaus, Rolf ;
Coboeken, Katrin ;
Gaub, Thomas ;
Kuepfer, Lars ;
Sensse, Anke ;
Siegmund, Hans-Ulrich ;
Weiss, Wolfgang ;
Mueck, Wolfgang ;
Lippert, Joerg .
PLOS ONE, 2011, 6 (04)
[7]  
Chahal Gurdip S, 2013, Ortop Traumatol Rehabil, V15, P125, DOI 10.5604/15093492.1045953
[8]   Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty [J].
Charters, Michael A. ;
Frisch, Nicholas B. ;
Wessell, Nolan M. ;
Dobson, Christopher ;
Les, Clifford M. ;
Silverton, Craig D. .
JOURNAL OF ARTHROPLASTY, 2015, 30 (07) :1277-1280
[9]   Rivaroxaban An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism [J].
Chen, Terry ;
Lam, Sum .
CARDIOLOGY IN REVIEW, 2009, 17 (04) :192-197
[10]   The use of rivaroxaban for short- and long-term treatment of venous thromboembolism [J].
Cohen, Alexander T. ;
Dobromirski, Mark .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (06) :1035-1043